Compounded GLP-1 drops or tablets vs injections: do the oral versions work?

Short answer: No—beware. Compounded “GLP‑1 drops” or DIY oral tablets are unlikely to work reliably and can be unsafe. If you want an oral GLP‑1 that’s been proven to work, use the single FDA‑approved product: Rybelsus (oral semaglutide). Otherwise use the approved injectable GLP‑1/dual‑agonists (Ozempic/Wegovy, Mounjaro/Zepbound) under a prescriber’s care.

Why compounded oral GLP‑1s are problematic

• Peptides are fragile. Native GLP‑1 drugs (semaglutide, tirzepatide) are broken down in the stomach and gut; making an effective oral version requires special formulation and absorption enhancers (for example, Rybelsus uses the SNAC technology). A simple compounded tablet or “sublingual” drop generally won’t reproduce that and may have negligible absorption.
• No clinical evidence. FDA approval requires controlled trials proving safety and dose‑response. Compounded versions lack that data, so you don’t know if they work or what dose you’re getting.
• Quality/safety risks. Compounded drugs can have incorrect potency, contaminants, or stability problems. Unlike FDA‑approved products, they don’t have the same manufacturing oversight or required labeling and safety data.
• Legal/regulatory/monitoring issues. Using unapproved formulations can complicate medical follow‑up and risk missing adverse events (pancreatitis, gallbladder disease, significant nausea, rare thyroid concerns).

Approved alternatives (proven, safer)

• Rybelsus (oral semaglutide tablet) — the only FDA‑approved oral GLP‑1. It has specific formulation and dosing rules (take fasting with water, wait ~30 minutes before eating/other meds).
• Ozempic (injectable semaglutide) — weekly injection for type 2 diabetes.
• Wegovy (injectable semaglutide 2.4 mg weekly) — approved for chronic weight management.
• Mounjaro (injectable tirzepatide) — approved for type 2 diabetes and shown strong weight‑loss effects.
• Zepbound (injectable tirzepatide) — approved for weight management (manufacturer/provider availability varies).

Practical advice

• Don’t use compounded GLP‑1 drops/tablets sold online without clear, reputable evidence and medical oversight.
• If you hate injections, ask your clinician about Rybelsus (oral semaglutide) or about injection options (pens are small, and many people find them acceptable after training).
• If cost or access is the issue, check manufacturer savings programs/patient assistance (Novo Nordisk programs for Ozempic/Wegovy/Rybelsus; Eli Lilly support for Mounjaro/Zepbound) or ask your clinician/pharmacy about prior authorization or alternatives.
• If you’re already taking a compounded product, stop it and talk to your prescriber about switching to an FDA‑approved option and getting appropriate monitoring.

If you’d like, tell me whether you’re asking for diabetes or weight‑loss treatment, whether you have trouble with injections, and whether cost/insurance is a concern—I can suggest specific FDA‑approved options and practical next steps.